Clinical Evidence

Abbott Point of Care (APOC) partners with physicians and researchers globally to advance scientific knowledge and evidence of our products in various clinical settings to help accelerate patient care.  Below is a compilation of peer reviewed journal articles and editorials demonstrating the clinical, analytical, operational, and economic value of APOC products.


Emergency Department


Click the blue titles below to launch the publication.

Title SOurce  Sample size Summary

Effect of Troponin I Point-of-Care Testing on Emergency Department Throughput Measures and Staff Satisfaction

Koehler et al 2013;

Objectives: Impact of point of care (POC) troponin testing on turnaround times, door-to-troponin result time, ED Length of Stay (LOS) in patients with chest pain, and staff satisfaction with POC testing was evaluated. 

Findings: Average door-to-troponin result time reduced significantly from 105 to 51 minutes with POC testing. Average LOS decreased from 290 to 255 minutes however this change was not significant. High satisfaction among ED staff members was reported.


CardioVascular Operating Room

Click the blue titles below to launch the publication.

Title SOurce  sample size Summary

Clinical Evaluation of Measuring the ACT During Elective Cardiac Surgery with Two Different Devices

Falter et al 2018;


Objectives: Multi-site study across UK, South Africa and Switzerland evaluated Activated Clotting Time (ACT) measurements with two devices, i-STAT and Hemochron Jr. Patients undergoing elective cardiac surgery on cardiopulmonary bypass were included.

Findings: i-STAT ACT test demonstrated good correlation with Hemochron Jr with i-STAT reading slightly higher than Hemochron Jr. Additionally, i-STAT consistently demonstrated lower within-subject coefficient of variation (WSCV) compared to Hemochron Jr, making it more reliable for clinical decision making. Authors commented that the better reliability of the i-STAT may be due to the difference in ACT methodology.

A Two Site Comparison of Two Point of Care Activated Clotting Time Systems

Kemna EW et al 2017;

Objectives: i-STAT Activated Clotting Time (ACT)  and Hemochron Signature Elite ACT values were compared using split samples from patients undergoing invasive surgery at two cardiothoracic institutes in the Netherlands and Germany.

Findings: i-STAT ACT values demonstrated better reproducibility (mean difference - 4.3% vs. 9.1%) and correlation compared to the Hemochron. In the therapeutic area (>250 s), Hemochron duplicate measurements became less precise. There are different possible explanations for the correlation results between the Hemochron and the i-STAT. The i-STAT is less susceptible to changes in fibrinogen levels, temperature, hematocrit and hemodilution compared to the Hemochron. These findings reflects precision and not accuracy. Since there is no true ACT value, clinicians rely on the precision (reproducibility) of tests.


outpatient settings

Click the blue titles below to launch the publication.

Title SOurce  sample size Summary

Economic Evaluation of Point-Of-Care Testing in the Remote Primary Health Care Setting of Australia’s Northern Territory

Spaeth et al 2018;

 Objectives: Economic value of i-STAT point-of-care (POCT) testing at six primary health care facilities in rural and remote communities in Australia, where hospital and laboratory facilities are unavailable were evaluated. Economic evaluation was conducted using data from patients presenting with three common acute conditions (chest pain, chronic renal failure due to missed dialysis session(s), and acute diarrhea).

The number of unnecessary medical evacuations prevented with the use of POCT as an aid in decision making for acutely ill patients was used as a basis of calculating cost savings per patient and Northern Territory (NT) wide.

Findings: Implementing POCT helped rule out 60 unnecessary medical evacuations during six-month study period. Associated cost savings per patient in chest pain, missed dialysis and acute diarrhea patient groups was AUS$ 4674, $8034 and  $786 respectively translating to NT wide savings of AUD $21.75 million per annum in total. The clinical and cost effectiveness of POCT in this study was only examined for three common acute presentation types, and may differ for other acute presentations.

The results shown here are specific to one health care facility and may differ from those achieved by other institutions.

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

Not optimized for your device

The page you are trying to access is best viewed on a desktop or laptop computer.

I want to view this page anyway
Contact us today